Company will receive $5 million initally, $17.3 million over a two-year period, with the potential to get another $22.1 million over the next three years.

Peregrine Pharmaceuticals was awarded a five-year contract by the DoD worth up to $44.4 million related to treatments for viral hemorrhagic fever infections. The firm will test and develop bavituximab and an equivalent fully human antibody.

Under the terms of the contact, Peregrine will recieve $5 million immediately. Over a 24-month base period, the company will have access to another $17.3 million for testing and development efforts. The contract can be extended beyond the base period to cover up to $44.4 million in funding over the five-year contract.

Bavituximab is the firm’s lead antiphosphatidylserine (anti-PS) mAb. It is currently in Phase I trials for HCV. The fully human anti-PS antibody to be assessed under this contract is currently in preclinical development.

The contract was awarded through the Transformational Medical Technologies Initiative of the DOD’s Defense Threat Reduction Agency (DTRA).

Previous articleLack of Protein in Neural Stem Cell Linked to Rett Syndrome
Next articleCancer Signal Level at which Tumorigenesis Reverts to Normal Cell Growth Identified in Mice